disease progression

Summary

Summary: The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.

Top Publications

  1. ncbi Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
    Roger Stupp
    Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    N Engl J Med 352:987-96. 2005
  2. doi New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
    E A Eisenhauer
    National Cancer Institute of Canada Clinical Trials Group, 10 Stuart Street, Queen s University, Kingston, Ontario, Canada
    Eur J Cancer 45:228-47. 2009
  3. ncbi MicroRNA signatures in human cancers
    George A Calin
    Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus, Ohio 43210, USA
    Nat Rev Cancer 6:857-66. 2006
  4. ncbi Epithelial-mesenchymal transitions in tumour progression
    Jean Paul Thiery
    Centre National Recherche Scientifique Unité Mixte Recherche, 144 Institut Curie, 26 Rue d Ulm, 75248 Paris Cedex 05, France
    Nat Rev Cancer 2:442-54. 2002
  5. pmc Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression
    John R Prensner
    Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Nat Biotechnol 29:742-9. 2011
  6. doi Sorafenib in advanced hepatocellular carcinoma
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Institut d Investigacions Biomediques August Pi i Sunyer, Centro de Investigaciones en Red de Enfermedades Hepáticas y Digestivas Hospital Clínic Barcelona, Barcelona
    N Engl J Med 359:378-90. 2008
  7. ncbi The nature of small-airway obstruction in chronic obstructive pulmonary disease
    James C Hogg
    University of British Columbia, the Centre for Cardiovascular and Pulmonary Research, and St Paul s Hospital, Vancouver, Canada
    N Engl J Med 350:2645-53. 2004
  8. ncbi Molecular requirements for epithelial-mesenchymal transition during tumor progression
    Margit A Huber
    Department of Dermatology, Vienna Medical University, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Curr Opin Cell Biol 17:548-58. 2005
  9. ncbi Fibroblasts in cancer
    Raghu Kalluri
    Center for Matrix Biology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Nat Rev Cancer 6:392-401. 2006
  10. pmc Abiraterone and increased survival in metastatic prostate cancer
    Johann S de Bono
    Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom
    N Engl J Med 364:1995-2005. 2011

Detail Information

Publications347 found, 100 shown here

  1. ncbi Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
    Roger Stupp
    Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    N Engl J Med 352:987-96. 2005
    ..In this trial we compared radiotherapy alone with radiotherapy plus temozolomide, given concomitantly with and after radiotherapy, in terms of efficacy and safety...
  2. doi New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
    E A Eisenhauer
    National Cancer Institute of Canada Clinical Trials Group, 10 Stuart Street, Queen s University, Kingston, Ontario, Canada
    Eur J Cancer 45:228-47. 2009
    ..feature of the clinical evaluation of cancer therapeutics: both tumour shrinkage (objective response) and disease progression are useful endpoints in clinical trials...
  3. ncbi MicroRNA signatures in human cancers
    George A Calin
    Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus, Ohio 43210, USA
    Nat Rev Cancer 6:857-66. 2006
    ..In addition, profiling has been exploited to identify miRNA genes that might represent downstream targets of activated oncogenic pathways, or that target protein-coding genes involved in cancer...
  4. ncbi Epithelial-mesenchymal transitions in tumour progression
    Jean Paul Thiery
    Centre National Recherche Scientifique Unité Mixte Recherche, 144 Institut Curie, 26 Rue d Ulm, 75248 Paris Cedex 05, France
    Nat Rev Cancer 2:442-54. 2002
  5. pmc Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression
    John R Prensner
    Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Nat Biotechnol 29:742-9. 2011
    ..These findings establish the utility of RNA-Seq to identify disease-associated ncRNAs that may improve the stratification of cancer subtypes...
  6. doi Sorafenib in advanced hepatocellular carcinoma
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Institut d Investigacions Biomediques August Pi i Sunyer, Centro de Investigaciones en Red de Enfermedades Hepáticas y Digestivas Hospital Clínic Barcelona, Barcelona
    N Engl J Med 359:378-90. 2008
    ..A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma...
  7. ncbi The nature of small-airway obstruction in chronic obstructive pulmonary disease
    James C Hogg
    University of British Columbia, the Centre for Cardiovascular and Pulmonary Research, and St Paul s Hospital, Vancouver, Canada
    N Engl J Med 350:2645-53. 2004
    ..We examined the evolution of the pathological effects of airway obstruction in patients with COPD...
  8. ncbi Molecular requirements for epithelial-mesenchymal transition during tumor progression
    Margit A Huber
    Department of Dermatology, Vienna Medical University, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Curr Opin Cell Biol 17:548-58. 2005
    ..Increasing evidence suggests that EMT plays a specific role in the migration of cells from a primary tumor into the circulation and may provide a rationale for developing more effective cancer therapies...
  9. ncbi Fibroblasts in cancer
    Raghu Kalluri
    Center for Matrix Biology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Nat Rev Cancer 6:392-401. 2006
    ..Fibroblasts are therefore a key determinant in the malignant progression of cancer and represent an important target for cancer therapies...
  10. pmc Abiraterone and increased survival in metastatic prostate cancer
    Johann S de Bono
    Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom
    N Engl J Med 364:1995-2005. 2011
    ..We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy...
  11. ncbi Circulating tumor cells, disease progression, and survival in metastatic breast cancer
    Massimo Cristofanilli
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 351:781-91. 2004
    ..We tested the hypothesis that the level of circulating tumor cells can predict survival in metastatic breast cancer...
  12. pmc Identification of cells initiating human melanomas
    Tobias Schatton
    Transplantation Research Center, Children s Hospital Boston and Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nature 451:345-9. 2008
    ..Identification of tumour-initiating cells with enhanced abundance in more advanced disease but susceptibility to specific targeting through a defining chemoresistance determinant has important implications for cancer therapy...
  13. pmc Distant metastasis occurs late during the genetic evolution of pancreatic cancer
    Shinichi Yachida
    Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Nature 467:1114-7. 2010
    ..These data provide novel insights into the genetic features underlying pancreatic cancer progression and define a broad time window of opportunity for early detection to prevent deaths from metastatic disease...
  14. ncbi Distinct role of macrophages in different tumor microenvironments
    Claire E Lewis
    Academic Unit of Pathology, Division of Genomic Medicine, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, United Kingdom
    Cancer Res 66:605-12. 2006
    ..This review will discuss the evidence for differential regulation of TAMs in these microenvironments and provide an overview of current attempts to target or use TAMs for therapeutic purposes...
  15. ncbi Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria
    Bruno Dubois
    INSERM U610, Hopital de la Salpetriere, Paris, France
    Lancet Neurol 6:734-46. 2007
    ..Validation studies in existing and prospective cohorts are needed to advance these criteria and optimise their sensitivity, specificity, and accuracy...
  16. ncbi Lapatinib plus capecitabine for HER2-positive advanced breast cancer
    Charles E Geyer
    Allegheny Cancer Center, Allegheny General Hospital, Pittsburgh, PA 15212, USA
    N Engl J Med 355:2733-43. 2006
    ..In this trial, we compared lapatinib plus capecitabine with capecitabine alone in such patients...
  17. ncbi The polycomb group protein EZH2 is involved in progression of prostate cancer
    Sooryanarayana Varambally
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Nature 419:624-9. 2002
    ..Thus, dysregulated expression of EZH2 may be involved in the progression of prostate cancer, as well as being a marker that distinguishes indolent prostate cancer from those at risk of lethal progression...
  18. ncbi The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies
    L Bingle
    Tumour Targeting Group, Division of Genomic Medicine, University of Sheffield Medical School, Sheffield S10 2RX, UK
    J Pathol 196:254-65. 2002
    ..It also outlines the range of pro- and anti-tumour functions performed by TAMs, and the novel therapies recently devised using TAMs to stimulate host immune responses or deliver therapeutic gene constructs to solid tumours...
  19. ncbi TGF-beta signaling in tumor suppression and cancer progression
    R Derynck
    Department of Growth and Development, University of California at San Francisco, San Francisco, California, USA
    Nat Genet 29:117-29. 2001
    ..Here we evaluate the role of TGF-beta in tumor development and attempt to reconcile the positive and negative effects of TGF-beta in carcinogenesis...
  20. ncbi Tumour-educated macrophages promote tumour progression and metastasis
    Jeffrey W Pollard
    Center for the Study of Reproductive Biology and Women s Health and the Albert Einstein Cancer Center, Albert Einstein College of Medicine, New York, New York 10461, USA
    Nat Rev Cancer 4:71-8. 2004
  21. ncbi Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200
    Bruce J Giantonio
    University of Pennsylvania, Philadelphia, PA, USA
    J Clin Oncol 25:1539-44. 2007
    ..This study was conducted to determine the effect of bevacizumab (at 10 mg/kg) on survival duration for oxaliplatin-based chemotherapy in patients with previously treated metastatic colorectal cancer...
  22. pmc Inflammation and cancer
    Lisa M Coussens
    Cancer Research Institute, Department of Pathology, University of California, San Francisco, California 94143, USA
    Nature 420:860-7. 2002
    ..These insights are fostering new anti-inflammatory therapeutic approaches to cancer development...
  23. ncbi Molecular determinants of resistance to antiandrogen therapy
    Charlie D Chen
    Department of Medicine, University of California at Los Angeles, Los Angeles, California 90095, USA
    Nat Med 10:33-9. 2004
    ..These findings provide insight toward the design of new antiandrogens...
  24. doi Design and endpoints of clinical trials in hepatocellular carcinoma
    Josep M Llovet
    HCC Translational Research Lab, Barcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clinic, CIBERehd, Institute for Biomedical Investigations August Pi Sunyer, Villarroel 170, 08036 Barcelona, Catalonia, Spain
    J Natl Cancer Inst 100:698-711. 2008
    ..These surrogate markers may help to enrich study populations and maximize the cost-benefit ratio of trial execution. Design and conduct of phase 3 trials should be coordinated by centers with appropriate expertise in HCC...
  25. ncbi Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression
    Sooryanarayana Varambally
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Cancer Cell 8:393-406. 2005
    ....
  26. ncbi Onset and progression in inherited ALS determined by motor neurons and microglia
    Severine Boillee
    Ludwig Institute for Cancer Research and Departments of Medicine and Neuroscience, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA
    Science 312:1389-92. 2006
    ..within motor neurons was shown to be a primary determinant of disease onset and of an early phase of disease progression. Diminishing the mutant levels in microglia had little effect on the early disease phase but sharply slowed ..
  27. ncbi New functions for the matrix metalloproteinases in cancer progression
    Mikala Egeblad
    Department of Anatomy, University of California at San Francisco, 94143 0452, USA
    Nat Rev Cancer 2:161-74. 2002
    ..With this knowledge in hand, can we rethink the use of MMP inhibitors in the clinic?..
  28. pmc Common genetic variation and the control of HIV-1 in humans
    Jacques Fellay
    Center for Human Genome Variation, Duke Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina, USA
    PLoS Genet 5:e1000791. 2009
    ..This study thus represents a comprehensive assessment of common human genetic variation in HIV-1 control in Caucasians...
  29. ncbi PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
    Cheryl L Day
    HIV Pathogenesis Programme, Doris Duke Medical Research Institute, University of KwaZulu Natal, Durban 4013, South Africa
    Nature 443:350-4. 2006
    ..cells, and expression correlates with impaired HIV-specific CD8 T-cell function as well as predictors of disease progression: positively with plasma viral load and inversely with CD4 T-cell count...
  30. ncbi Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?
    Hector Peinado
    Departamento de Bioquimica, Facultad de Medicina, Universidad Autonoma de Madrid UAM, Instituto de Investigaciones Biomedicas Alberto Sols CSIC UAM, Arturo Duperier 4, 28029 Madrid, Spain
    Nat Rev Cancer 7:415-28. 2007
    ....
  31. ncbi NF-kappaB functions as a tumour promoter in inflammation-associated cancer
    Eli Pikarsky
    Department of Pathology, Hadassah Hebrew University Medical Center, Jerusalem 91120, Israel
    Nature 431:461-6. 2004
    ..Our studies thus indicate that NF-kappaB is essential for promoting inflammation-associated cancer, and is therefore a potential target for cancer prevention in chronic inflammatory diseases...
  32. pmc A whole-genome association study of major determinants for host control of HIV-1
    Jacques Fellay
    Center for Population Genomics and Pharmacogenetics, Duke Institute for Genome Sciences and Policy, Duke University, Durham, NC 27710, USA
    Science 317:944-7. 2007
    ..An additional analysis of the time to HIV disease progression implicated two genes, one of which encodes an RNA polymerase I subunit...
  33. ncbi Multiple sclerosis--the plaque and its pathogenesis
    Elliot M Frohman
    Department of Neurology and Ophthalmology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA
    N Engl J Med 354:942-55. 2006
  34. ncbi Tumorigenesis and the angiogenic switch
    Gabriele Bergers
    University of California San Francisco, Department of Neurological Surgery, Brain Tumor Research Center and Comprehensive Cancer Center, HSE 722, 513 Parnassus Avenue, San Francisco, California 94143 0520, USA
    Nat Rev Cancer 3:401-10. 2003
    ....
  35. ncbi Lysyl oxidase is essential for hypoxia-induced metastasis
    Janine T Erler
    Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California 94305, USA
    Nature 440:1222-6. 2006
    ..Furthermore, LOX may be required to create a niche permissive for metastatic growth. Our findings indicate that LOX is essential for hypoxia-induced metastasis and is a good therapeutic target for preventing and treating metastases...
  36. ncbi Epithelial--mesenchymal and mesenchymal--epithelial transitions in carcinoma progression
    Honor Hugo
    Embryology Laboratory, Murdoch Children s Research Institute, The Royal Children s Hospital, Victoria, Australia
    J Cell Physiol 213:374-83. 2007
    ..Finally, perspectives from a clinical and translational viewpoint are discussed...
  37. pmc Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
    Leslie M Shaw
    Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Ann Neurol 65:403-13. 2009
    ..Develop a cerebrospinal fluid biomarker signature for mild Alzheimer's disease (AD) in Alzheimer's Disease Neuroimaging Initiative (ADNI) subjects...
  38. ncbi Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression
    Maria Manczak
    Neurogenetics Laboratory, Neurological Sciences Institute, Oregon Health and Science University, 505 NW 185th Aveue, Beaverton, 97006, USA
    Hum Mol Genet 15:1437-49. 2006
    ..These findings suggest that early mitochondrially targeted therapeutic interventions may be effective in delaying AD progression in elderly individuals and in treating AD patients...
  39. pmc The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis
    Stephanie Debette
    Clinical Neuroscience, St George s University of London, London
    BMJ 341:c3666. 2010
    ..To review the evidence for an association of white matter hyperintensities with risk of stroke, cognitive decline, dementia, and death...
  40. ncbi Matrix metalloproteinases and tumor metastasis
    Elena I Deryugina
    Department of Cell Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
    Cancer Metastasis Rev 25:9-34. 2006
    ..This dual function of individual MMPs in metastasis has become a major focus of this review...
  41. ncbi Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis
    Heidi S Phillips
    Department of Tumor Biology and Angiogenesis, Genentech, Inc, South San Francisco, California 94080, USA
    Cancer Cell 9:157-73. 2006
    ..A robust two-gene prognostic model utilizing PTEN and DLL3 expression suggests that Akt and Notch signaling are hallmarks of poor prognosis versus better prognosis gliomas, respectively...
  42. pmc TGFbeta in Cancer
    Joan Massague
    Cancer Biology and Genetics Program, and Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cell 134:215-30. 2008
    ..The mechanistic basis and clinical relevance of TGFbeta's role in cancer is becoming increasingly clear, paving the way for a better understanding of the complexity and therapeutic potential of this pathway...
  43. pmc Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis
    Koji Yamanaka
    Ludwig Institute for Cancer Research and Department of Medicine and Neuroscience, University of California at San Diego, 9500 Gilman Drive, La Jolla, California 92093 0670, USA
    Nat Neurosci 11:251-3. 2008
    ..expression in astrocytes did not affect onset, but delayed microglial activation and sharply slowed later disease progression. These findings demonstrate that mutant astrocytes are viable targets for therapies for slowing the ..
  44. pmc Stromal fibroblasts in cancer initiation and progression
    Neil A Bhowmick
    Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    Nature 432:332-7. 2004
    ..Recent studies reveal that fibroblasts have a more profound influence on the development and progression of carcinomas than was previously appreciated. These new findings have important therapeutic implications...
  45. ncbi Sorafenib in advanced clear-cell renal-cell carcinoma
    Bernard Escudier
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    N Engl J Med 356:125-34. 2007
    ..We conducted a phase 3, randomized, double-blind, placebo-controlled trial of sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, in patients with advanced clear-cell renal-cell carcinoma...
  46. ncbi The epigenetic progenitor origin of human cancer
    Andrew P Feinberg
    Department of Medicine, Johns Hopkins University School of Medicine, 720 Rutland Avenue, Baltimore, Maryland 21205, USA
    Nat Rev Genet 7:21-33. 2006
    ..Therefore, non-neoplastic but epigenetically disrupted stem/progenitor cells might be a crucial target for cancer risk assessment and chemoprevention...
  47. ncbi Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy
    Steven G Deeks
    University of California, San Francisco, and San Francisco General Hospital, San Francisco, CA 94110, USA
    Immunity 27:406-16. 2007
    ..Further understanding of the mechanisms whereby this occurs should yield critical insights for prophylactic and therapeutic antiviral interventions...
  48. ncbi Tumour biology: senescence in premalignant tumours
    Manuel Collado
    Spanish National Cancer Centre CNIO, Madrid 28029, Spain
    Nature 436:642. 2005
    ..Senescence is therefore a defining feature of premalignant tumours that could prove valuable in the diagnosis and prognosis of cancer...
  49. ncbi Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials
    Richard J Sylvester
    EORTC Data Center, Brussels, Belgium
    Eur Urol 49:466-5; discussion 475-7. 2006
    ..To provide tables that allow urologists to easily calculate a superficial bladder cancer patient's short- and long-term risks of recurrence and progression after transurethral resection...
  50. ncbi Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS
    Maureen P Martin
    Basic Research Program, SAIC Frederick, Frederick, Maryland 21702 1201, USA
    Nat Genet 31:429-34. 2002
    ..The strongest synergistic effect of these loci was on progression to depletion of CD4(+) T cells, which suggests that a protective response of NK cells involving KIR3DS1 and its HLA class I ligands begins soon after HIV-1 infection...
  51. pmc Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases
    Elaine Y Lin
    Center for Study of Reproductive Biology and Women s Health, Departments of Developmental and Molecular Biology Obstetrics and Gynecology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA
    Am J Pathol 163:2113-26. 2003
    ..An increased leukocytic infiltration was also closely associated with the malignant transition. This study demonstrates that the PyMT mouse model is an excellent one to understand the biology of tumor progression in humans...
  52. ncbi Predictors of long-term progression in the early manifest glaucoma trial
    M Cristina Leske
    Department of Preventive Medicine, Stony Brook University Medical Center, Stony Brook, New York 11794 8036, USA
    Ophthalmology 114:1965-72. 2007
    ..To determine progression factors at the end of the Early Manifest Glaucoma Trial (EMGT) based on all EMGT patients and evaluate separately patients with higher and lower baseline intraocular pressure (IOP; median split)...
  53. ncbi Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    D J Slamon
    Division of Hematology and Oncology, UCLA School of Medicine, Los Angeles, Calif 90095 1678, USA
    N Engl J Med 344:783-92. 2001
    ..The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 percent of breast cancers, increasing the aggressiveness of the tumor...
  54. doi E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer
    Otto Schmalhofer
    Department of Visceral Surgery, University of Freiburg, Hugstetter Strasse 55, 79106, Freiburg, Germany
    Cancer Metastasis Rev 28:151-66. 2009
    ....
  55. pmc Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses
    Eric M Blalock
    Department of Molecular and Biomedical Pharmacology, Spinal Cord and Brain Injury Research Center, and Sanders Brown Research Center on Aging, University of Kentucky College of Medicine, Lexington, KY 40536, USA
    Proc Natl Acad Sci U S A 101:2173-8. 2004
    ..These findings suggest a new model of AD pathogenesis in which a genomically orchestrated up-regulation of tumor suppressor-mediated differentiation and involution processes induces the spread of pathology along myelinated axons...
  56. ncbi From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I
    Morteza Naghavi
    The Center for Vulnerable Plaque Research, University of Texas Houston, The Texas Heart Institute, and President Bush Center for Cardiovascular Health, Memorial Hermann Hospital, Houston, USA
    Circulation 108:1664-72. 2003
    ..We encourage healthcare policy makers to promote translational research for screening and treatment of vulnerable patients...
  57. pmc A network diffusion model of disease progression in dementia
    Ashish Raj
    Department of Radiology, Weill Medical College of Cornell University, 515 E 71 Street, Suite S123, New York, NY 10044, USA
    Neuron 73:1204-15. 2012
    ..This work has many important implications, including dimensionality reduction, differential diagnosis, and especially prediction of future atrophy using baseline MRI morphometrics...
  58. pmc An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression
    Jindan Yu
    Michigan Center for Translational Pathology, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Cancer Cell 17:443-54. 2010
    ..These findings provide a working model in which TMPRSS2-ERG plays a critical role in cancer progression by disrupting lineage-specific differentiation of the prostate and potentiating the EZH2-mediated dedifferentiation program...
  59. doi SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis
    Hye Jung Han
    Life Sciences Division, Lawrence Berkeley National Laboratory, University of California, Berkeley, California 94720, USA
    Nature 452:187-93. 2008
    ..SATB1 reprogrammes chromatin organization and the transcription profiles of breast tumours to promote growth and metastasis; this is a new mechanism of tumour progression...
  60. doi Microglia in ALS: the good, the bad, and the resting
    Jenny S Henkel
    Department of Neurology, Methodist Neurological Institute, The Methodist Hospital Research Institute, The Methodist Hospital, 6560 Fannin Street, Houston, TX 77030, USA
    J Neuroimmune Pharmacol 4:389-98. 2009
    ..The microglial and T cell activation states influence the rate of disease progression. Initially, microglia and T cells can slow disease progression, while they may later contribute to the ..
  61. doi K-ras mutations and benefit from cetuximab in advanced colorectal cancer
    Christos S Karapetis
    Flinders Medical Centre and Flinders University, Adelaide, Australia
    N Engl J Med 359:1757-65. 2008
    ..The mutation status of the K-ras gene in the tumor may affect the response to cetuximab and have treatment-independent prognostic value...
  62. ncbi BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
    Scott M Wilhelm
    Bayer Pharmaceuticals Corporation, West Haven, Connecticut 06516, USA
    Cancer Res 64:7099-109. 2004
    ..These data demonstrate that BAY 43-9006 is a novel dual action RAF kinase and VEGFR inhibitor that targets tumor cell proliferation and tumor angiogenesis...
  63. ncbi Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis
    F D Lublin
    Department of Neurology, Jefferson Medical College, Philadelphia, PA, USA
    Neurology 46:907-11. 1996
    ..In this report, we provide a summary of the survey results and propose standardized definitions for the most common clinical courses of patients with MS...
  64. ncbi Cortical demyelination and diffuse white matter injury in multiple sclerosis
    Alexandra Kutzelnigg
    Center for Brain Research, Medical University of Vienna, Vienna, Austria
    Brain 128:2705-12. 2005
    ..With chronicity, diffuse inflammation accumulates throughout the whole brain, and is associated with slowly progressive axonal injury in the NAWM and cortical demyelination...
  65. ncbi Persistent immune activation in HIV-1 infection is associated with progression to AIDS
    Mette D Hazenberg
    Department of Clinical Viro Immunology, Sanquin Research at CLB, Tropical Medicine and AIDS, Amsterdam, The Netherlands
    AIDS 17:1881-8. 2003
    ..HIV-1 infection is characterized by chronic generalized CD8 and CD4 T cell hyperactivation, the biological effect of which is not understood...
  66. doi Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study
    Bartolome R Celli
    Tufts University School of Medicine, Pulmonary and Critical Care Division, Caritas St Elizabeth s Medical Center, Boston, MA 02135 2997, USA
    Am J Respir Crit Care Med 178:332-8. 2008
    ..Chronic obstructive pulmonary disease (COPD) is characterized by an accelerated decline in lung function. No drug has been shown conclusively to reduce this decline...
  67. ncbi Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction
    Daniel E Kaufmann
    Partners AIDS Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nat Immunol 8:1246-54. 2007
    ..CTLA-4 expression correlated positively with disease progression and negatively with the capacity of CD4(+) T cells to produce interleukin 2 in response to viral antigen...
  68. doi Platinum-based chemotherapy plus cetuximab in head and neck cancer
    Jan B Vermorken
    Antwerp University Hospital, Department of Medical Oncology, Edegem, Belgium
    N Engl J Med 359:1116-27. 2008
    ..We investigated the efficacy of cetuximab plus platinum-based chemotherapy as first-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck...
  69. doi Changes in forced expiratory volume in 1 second over time in COPD
    Jørgen Vestbo
    Respiratory Section, Hvidovre Hospital, Hvidovre, Denmark
    N Engl J Med 365:1184-92. 2011
    ....
  70. doi Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer
    Eric Van Cutsem
    University Hospital Gasthuisberg, Digestive Oncology Unit, Herestraat 49, 3000 Leuven, Belgium
    N Engl J Med 360:1408-17. 2009
    ....
  71. ncbi Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection
    Eberhard W Fiebig
    Department of Laboratory Medicine, University of California, San Francisco, CA, USA
    AIDS 17:1871-9. 2003
    ..The characterization of primary HIV infection by the analysis of serial plasma samples from newly infected persons using multiple standard viral assays...
  72. pmc Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
    E L Jackson
    Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
    Genes Dev 15:3243-8. 2001
    ..Of particular significance, this system has led to the identification of a new cell type contributing to the development of pulmonary adenocarcinoma...
  73. doi Alzheimer's disease: strategies for disease modification
    Martin Citron
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Nat Rev Drug Discov 9:387-98. 2010
    ..However, in recent years, several approaches aimed at inhibiting disease progression have advanced to clinical trials...
  74. ncbi Tumor stroma and regulation of cancer development
    Thea D Tlsty
    Department of Pathology and Comprehensive Cancer Center, University of California, San Francisco, California 94115, USA
    Annu Rev Pathol 1:119-50. 2006
    ....
  75. ncbi Apoptosis and melanoma chemoresistance
    Maria S Soengas
    Department of Dermatology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 28109, USA
    Oncogene 22:3138-51. 2003
    ..With this knowledge in hand, the challenge is now to devise strategies potent enough to compensate or bypass these cell death defects and improve the actual poor prognosis of patients at late stages of the disease...
  76. ncbi Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy
    Yan Ping Yu
    University of Pittsburgh Cancer Institute and Department of Pathology, University of Pittsburgh, 3550 Terrace Street, Pittsburgh, PA 15261, USA
    J Clin Oncol 22:2790-9. 2004
    ..Despite the advances in our understanding of prostate carcinogenesis and disease progression, our knowledge of this disease is still fragmented...
  77. pmc Inferring tumor progression from genomic heterogeneity
    Nicholas Navin
    Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA
    Genome Res 20:68-80. 2010
    ..By comparing multiple subpopulations from different anatomic locations, we have inferred pathways of cancer progression and the organization of tumor growth...
  78. pmc Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis
    Marta Pàez-Ribes
    Translational Research Laboratory, Catalan Institute of Oncology, IDIBELL, 08907 L Hospitalet de Llobregat, Spain
    Cancer Cell 15:220-31. 2009
    ....
  79. ncbi Melanoma
    Arlo J Miller
    Dermatopathology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    N Engl J Med 355:51-65. 2006
  80. pmc Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression
    Takashi Matsushita
    Department of Immunology, Duke University Medical Center, Durham, North Carolina, USA
    J Clin Invest 118:3420-30. 2008
    ..regulatory B10 cells was maximally effective during early EAE initiation, they had no obvious role during disease progression. Rather, B cell depletion during EAE disease progression dramatically suppressed symptoms...
  81. pmc Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 26:1148-59. 2008
    ..To update eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone...
  82. ncbi Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy
    Antonio Sica
    Istituto Clinico Humanitas, 20089 Rozzano, Milan, Italy
    Eur J Cancer 42:717-27. 2006
    ..Evidence is presented here supporting the view that TAM represent a unique and distinct M2-skewed myeloid population and are a potential target for anti-cancer therapy...
  83. doi Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)
    Axel Grothey
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 26:5326-34. 2008
    ..1 months was reported. The association between various pre- and post-treatment factors (including the use of bevacizumab beyond first progression [BBP]) and survival was examined...
  84. doi Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT
    Charles D Blanke
    Oregon Health and Science University Cancer Center and Portland Veterans Affairs Hospital, Portland, OR, USA
    J Clin Oncol 26:620-5. 2008
    ..We conducted a long-term analysis of patients treated on the trial, including patients followed during an extension phase, to evaluate survival, patterns of failure, and potential prognostic factors, including tumor mutational status...
  85. ncbi Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:8253-61. 2005
    ..On the basis of this schema, we discuss strategies that are focused on the AR either directly or indirectly, as single agents or in combination, that are in clinical development...
  86. ncbi Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells
    Michael F Clarke
    Stanford University School of Medicine, Stanford, California, USA
    Cancer Res 66:9339-44. 2006
  87. pmc A tense situation: forcing tumour progression
    Darci T Butcher
    Department of Surgery and Center for Bioengineering and Tissue Regeneration, University of California at San Francisco, San Francisco, California 94143, USA
    Nat Rev Cancer 9:108-22. 2009
    ..Moreover, the mechanical properties of a tissue contribute to disease progression, compromise treatment and might also alter cancer risk...
  88. ncbi The spectrum of neuromyelitis optica
    Dean M Wingerchuk
    Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
    Lancet Neurol 6:805-15. 2007
    ..The knowledge gained from further assessment of the exact role of NMO-IgG in the pathogenesis of neuromyelitis optica will provide a foundation for rational therapeutic trials for this rapidly disabling disease...
  89. doi Genetic variegation of clonal architecture and propagating cells in leukaemia
    Kristina Anderson
    Section of Haemato oncology, The Institute of Cancer Research, Sutton SM2 5NG, UK
    Nature 469:356-61. 2011
    ..These data have implications for cancer genomics and for the targeted therapy of cancer...
  90. doi Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
    Gerhardt Attard
    Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
    J Clin Oncol 26:4563-71. 2008
    ..To evaluate this, a trial of abiraterone acetate-a potent, selective, small-molecule inhibitor of cytochrome P (CYP) 17, a key enzyme in androgen synthesis-was pursued...
  91. doi Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma
    Shunsuke Ura
    Department of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan
    Hepatology 49:1098-112. 2009
    ....
  92. ncbi Emerging roles of proteases in tumour suppression
    Carlos Lopez-Otin
    Carlos López Otín is at the Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Instituto Universitario de Oncologia, Universidad de Oviedo, 33006 Oviedo, Spain
    Nat Rev Cancer 7:800-8. 2007
    ..These effects are associated with more than 30 different enzymes that belong to three distinct protease classes. What are the clinical implications of these findings?..
  93. doi A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
    David Cameron
    University of Leeds, Leeds, England, UK
    Breast Cancer Res Treat 112:533-43. 2008
    ..Updated efficacy and initial biomarker results from this trial are reported...
  94. ncbi A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
    Chris H Polman
    Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    N Engl J Med 354:899-910. 2006
    ..Natalizumab is the first alpha4 integrin antagonist in a new class of selective adhesion-molecule inhibitors. We report the results of a two-year phase 3 trial of natalizumab in patients with relapsing multiple sclerosis...
  95. doi A 4-year trial of tiotropium in chronic obstructive pulmonary disease
    Donald P Tashkin
    David Geffen School of Medicine at the University of California, Los Angeles 90095 1690, USA
    N Engl J Med 359:1543-54. 2008
    ..Previous studies showing that tiotropium improves multiple end points in patients with chronic obstructive pulmonary disease (COPD) led us to examine the long-term effects of tiotropium therapy...
  96. ncbi Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions
    Vassilis G Gorgoulis
    Department of Histology and Embryology, School of Medicine, University of Athens, Athens GR 11527, Greece
    Nature 434:907-13. 2005
    ..We propose that, from its earliest stages, cancer development is associated with DNA replication stress, which leads to DNA double-strand breaks, genomic instability and selective pressure for p53 mutations...
  97. pmc Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis
    Ie Ming Shih
    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Am J Pathol 164:1511-8. 2004
    ..This model of carcinogenesis reconciles the relationship of borderline tumors to invasive carcinoma and provides a morphological and molecular framework for studies aimed at elucidating the pathogenesis of ovarian cancer...
  98. ncbi Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization
    Douglas S Keith
    Division of Nephrology and Hypertension, Oregon Health and Science University, USA
    Arch Intern Med 164:659-63. 2004
    ..The purpose of this study was to understand the natural history of chronic kidney disease with regard to progression to renal replacement therapy (transplant or dialysis) and death in a representative patient population...
  99. doi Astrocyte elevated gene-1 is a novel prognostic marker for breast cancer progression and overall patient survival
    Jun Li
    Key Laboratory of Tropical Disease Control Sun Yat sen University, Ministry of Education, Guangzhou, Guangdong, China
    Clin Cancer Res 14:3319-26. 2008
    ....
  100. ncbi Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
    Jerome Galon
    INSERM U 255, Paris, 75006 France Université Paris Descartes Paris 5, Faculte de Medecine, Paris, 75006 France
    Science 313:1960-4. 2006
    ..In situ analysis of tumor-infiltrating immune cells may therefore be a valuable prognostic tool in the treatment of colorectal cancer and possibly other malignancies...
  101. ncbi Long-term follow-up of patients with NAFLD and elevated liver enzymes
    Mattias Ekstedt
    Division of Gastroenterology and Hepatology, Department of Molecular and Clinical Medicine, University Hospital, Linkoping, Sweden
    Hepatology 44:865-73. 2006
    ..Most NAFLD patients will develop diabetes or impaired glucose tolerance in the long term. Progression of liver fibrosis is associated with more pronounced insulin resistance and significant weight gain...

Research Grants72

  1. STATISITICAL DESIGN, MONITORING &COORD. OF VISION CLINICAL TRIALS &EPIDEMIOLOGY
    Keri Hammel; Fiscal Year: 2012
    ..Researchers are interested in comparing eye disease progression in people using the ForeseeHome device with those not using the device...
  2. STATISITICAL DESIGN, MONITORING &COORD. OF VISION CLINICAL TRIALS &EPIDEMIOLOGY
    Keri Hammel; Fiscal Year: 2013
    ..Researchers are interested in comparing eye disease progression in people using the ForeseeHome device with those not using the device...
  3. Personalized Clinical Diagnostics and Beyond: Integrated Ring Resonator Arrays
    Ryan Bailey; Fiscal Year: 2009
    ..This technology promises to broadly impact the landscape of the biomedical sciences, both meeting the clinical diagnostic challenges of today and pioneering the paradigm-shifting discoveries of tomorrow. ..
  4. Importance of antigen specific immunoglobulin responses in controlling SIV/SHIV i
    Bapi Pahar; Fiscal Year: 2010
    ..with marginal decreases in viral loads, yet these do not correlate with protection from infection or disease progression. However, In addition to CTL, B-lymphocytes also play an important role in the immune response to infection ..
  5. Angiotensin Adrenergic Interactions in the Kidney
    Roland C Blantz; Fiscal Year: 2013
    ..We will examine further the effects of maneuvers that reduce oxygen consumption on disease progression at 4 weeks after subtotal nephrectomy...
  6. Epigenetic mechanisms relevant to the pathogenesis of ALS
    Neil W Kowall; Fiscal Year: 2013
    ..We recently reported that the amino acid L-arginine slows disease progression in mutant SOD1 (G93A) transgenic ALS mice...
  7. Regulation of mural cells during pulmonary capillary formation
    Stephen E McGowan; Fiscal Year: 2013
    ..most of the currently available therapies only address symptoms, identification of strategies that limit disease progression remains an important goal...
  8. Novel PET imaging agents for early diagnosis of plaque deposition in Alzheimer's
    Padmakar Kulkarni; Fiscal Year: 2010
    ..with Alzheimer's disease (AD) and also would allow for specific and accurate early diagnosis and disease progression and disease modifying treatments...
  9. Transgenesis and Xenotransplantation
    Jorge A Piedrahita; Fiscal Year: 2013
    ..system development and function, study development and treatment for diseases such as leukemia, looking at disease progression and the development of vaccines for diseases such as AIDS, and study human tumor progression and treatment...
  10. Pathobiology of Cystic Fibrosis-Related Diabetes in a Ferret Model
    Zoe Stewart; Fiscal Year: 2013
    ..Finally, we will evaluate the impact of pancreatic CFTR gene therapy on the progression of early pulmonary disease progression in CF ferrets following removal of antibiotics...
  11. ICSBP Function During Myeloid Differentiation
    ELIZABETH ANN EKLUND; Fiscal Year: 2011
    ..Aim 3: Identify genetic lesions that cooperate with ICSBP-deficiency to lead to disease progression in myeloid malignancy...
  12. Bisphosphonates in the treatment of chronic kidney disease-mineral bone disease
    Sharon M Moe; Fiscal Year: 2013
    ..and bone loss, arterial calcification, and left ventricular hypertrophy, accurately reflecting the clinical disease progression observed in humans with CKD...
  13. Novel diagnostic and safety biomarkers of liver injury and hepatotoxicity
    Stanislav I Svetlov; Fiscal Year: 2010
    ..data including liver biopsy, serological and laboratory data with an emphasis on hepatic injury severity, disease progression and outcome...
  14. Structural Basis for Chemokine Function
    Brian F Volkman; Fiscal Year: 2013
    ..We will also investigate the ability of engineered SDF1 monomers and dimers to alter disease progression in animal models for human diseases including multiple sclerosis, ulcerative colitis, and metastatic cancer...
  15. MR Monitoring of PTC124 Treatment in DMD
    KRISTA H VANDENBORNE; Fiscal Year: 2010
    ..study is to validate the potential of magnetic resonance imaging (MRI) and spectroscopy (MRS) to monitor disease progression and the response to therapeutic interventions in children with DMD...
  16. Molecular Mechanisms of Disease Progression in Myeloid Malignancy
    ELIZABETH ANN EKLUND; Fiscal Year: 2013
    ..AIM 2: Determine if Icsbp contributes to disease progression by inhibiting Gsk3[unreadable] or increasing Stat3 in CML-LSC...
  17. Effects of Standardized Aerobic Exercise-Training on Neurocognitive and Neurodege
    Thomas O Obisesan; Fiscal Year: 2010
    ..have greatly improved symptomatic treatment of AD, they have not been demonstrated to significantly slow disease progression. Excess morbidity and mortality from AD continue to generate an enormous economic burden on families and on ..
  18. Role of Retroelements in Environmental Atherogenesis
    Kenneth S Ramos; Fiscal Year: 2010
    ..are proposed in this application to evaluate the expression of L1 during the course of atherosclerotic disease progression in the Apoetm1Unc mouse model, to evaluate the impact of vascular specific expression of L1 on ..
  19. Modifiers of Cyst Progression in Polycystic Kidney Disease
    Phillip Darwin Bell; Fiscal Year: 2013
    ..Thus, hypertrophic signaling and hyperglycemia may be two extremely important regulators of disease progression in PKD...
  20. Inhibition of bone formation by Prx1
    Mark S Nanes; Fiscal Year: 2013
    ..identified the mechanism of osteoclastogenesis and bone resorption, and provided new medications to arrest disease progression. Despite this, there is little understanding of why eroded articular bone fails to heal...
  21. Transplacental Arsenic Induced Hepatic Dysfunction and Vascular Disease
    J Christopher States; Fiscal Year: 2010
    ..on the mechanisms of arsenic induced atherosclerosis and the role that fetal arsenic exposure plays in disease progression. This model also will be a rich resource for future research on the mechanism of arsenic induced ..
  22. Neuroimaging Assessments of Brain Integrity in Aging Mice
    Ai Ling Lin; Fiscal Year: 2013
    ..because 1) physiological effects of metabolic alterations in aging and age-related neuronal disorders, disease progression and treatment efficacy can be monitored non-invasively and nondestructively;2) the interplay between brain ..
  23. Hepatic Steatosis and ER Stress-Inducible Transcription Factor CREBH
    Kezhong Zhang; Fiscal Year: 2013
    ..b>Disease progression in NAFLD is currently thought to be triggered by an acute insult (the "second hit") that is imposed on ..
  24. Role of Potent Trophic Factors on Glia and Motor Neurons in ALS
    Brian K Kaspar; Fiscal Year: 2013
    ..VEGF) delivered at disease onset in ALS rodent models have demonstrated profound effects in delaying disease progression. Recent studies have surprisingly demonstrated that astrocytes and microglia expressing a mutation in the ..
  25. Role of Platelet derived growth factor receptor-a in Liver Patho-biology
    SATDARSHAN SINGH MONGA; Fiscal Year: 2013
    ..by utilization of species-specific PDGFR[unreadable] blocking antibodies to determine impact on disease progression in these models to address therapeutic efficacy...
  26. Mechanism(s) of Hepatocyte Transformation by the Hepatitis B Virus X Protein
    Ourania M Andrisani; Fiscal Year: 2013
    ..protein levels of Plk1, SUZ12, ZNF198, and expression of known SUZ12 target genes are prognostic for disease progression and survival. Impact: High level of viremia in chronic HBV patients is a risk factor for progression to HCC...
  27. The Role of Alcohol in HIV Therapy Hepatotoxicity
    Craig J McClain; Fiscal Year: 2012
    ..Patients who consume alcohol also may be less compliant with their HIV therapy, which can affect disease progression. The research focus of this grant is the potential impact of alcohol use/abuse as a co-factor for HIV ..
  28. New drug Vida-5 for treating chronic kidney disease progression
    Jinshyun Ruth Wu-Wong; Fiscal Year: 2011
    ..treatments available, the five-year survival rate is ~33% and the mortality risk increases with kidney disease progression and secondary hyperparathyroidism...
  29. Mechanisms of Early Growth Response Factor 1 (Egr-1) Induction by HSV-1 Lytic Inf
    SHAOCHUNG VICTOR HSIA; Fiscal Year: 2010
    ..is efficiently induced upon HSV-1 lytic infection and may play a key role in the viral replication and the disease progression in eyes...
  30. Role of troponin T isoforms in nemaline myopathy
    Jian Ping Jin; Fiscal Year: 2012
    ..in which the ANM nonsense mutation is knocked in the slow TnT gene to investigate the pathogenesis and disease progression. Aim II: To examine the conditional effects of slow TnT gene haploidy and cytotoxicity of the truncated ..
  31. Novel drug VS-105 for treatment of diabetic nephropathy
    Jinshyun Ruth Wu-Wong; Fiscal Year: 2012
    ..treatments available, the five-year survival rate is ~33% and the mortality risk increases with kidney disease progression and secondary hyperparathyroidism...
  32. Oxidative Stress in Chronic Kidney Disease
    Talat Alp Ikizler; Fiscal Year: 2012
    ..new preliminary data demonstrates that levels of physical activity are closely associated with kidney disease progression. These findings suggest that interventions targeting caloric excess, reduced physical activity, and ..
  33. Hiv-1 Infection: Central Serotonergic Activity and its Health Implications
    Adarsh M Kumar; Fiscal Year: 2010
    ..and affects their quality of life, interferes in adherence to treatment, and is a risk factor for disease progression, and mortality...
  34. Enhance Production of Functional Recombinant Human Protein C Variant In Mammalian
    Nienwen Chow; Fiscal Year: 2010
    ..a mutant form of activated protein C (APC) with minimal anticoagulant activity, designated as 5A-APC, slows disease progression and extends the lifespan and the symptomatic phase...
  35. Genomic adaptation to HIV infection of the CNS in opioid-abusers
    Rajnish S Dave; Fiscal Year: 2012
    ..Collectively, these circumstances accelerate HIV disease progression. Inflammation and oxidative stress are some of the well- characterized reactions induced by these ..
  36. Evaluating Novel Multi-kinase Peptide Inhibitors as a Treatment for Rheumatoid Ar
    DAVID MEN HWEI TSAI; Fiscal Year: 2013
    ..chronic inflammation and reactive oxygen species create a negative feedback loop that accelerates disease progression. In the synovium of RA patients, fibroblast-like synoviocytes (RA- FLS) has features of tumor-like ..
  37. Glutathione in mitochondrial dysfunction and disease progression in ALS-models
    Marcelo R Vargas; Fiscal Year: 2011
    ..The proposal is designed to determine the effect of reduced GSH content in mitochondrial pathology and disease progression in ALS...
  38. A novel allele influencing HIV infection among injection drug users
    Xiao Fang Yu; Fiscal Year: 2012
    ..genomes encoding chemokines and their receptors are associated with altered rates of HIV-1 infection and disease progression. However, these studies have mainly been conducted in Caucasian and African American populations...
  39. Biomarker Reference Laboratory, EDRN
    William E Grizzle; Fiscal Year: 2010
    ..on disease progression. The expertise of the core investigators is complemented by the resources available though the UAB ..
  40. Inhibitors of the Y. pestis cell surface plasminogen activator for biodefense
    Marjorie H Barnes; Fiscal Year: 2010
    ..mice (LD50 increases from 50 to 107 bacterial cells) and significantly reduces the rapidity of pneumonic disease progression. Furthermore, homologous omptins are virulence factors in E...
  41. Over-Expression of microRNA-126 in Macrophages for Treatment of Atherosclerosis
    Suzette Laing; Fiscal Year: 2013
    ..The continued monocyte recruitment and cholesterol accumulation in the vessel wall facilitates chronic disease progression. The identification of several subsets of microRNAs involved in vascular repair and homeostasis have made ..
  42. Impact of AMP-activated kinase on sex differences in hypertrophic cardiomyopathy
    John P Konhilas; Fiscal Year: 2013
    ..the predominant motor protein in the heart (1-myosin heavy chain) show a similar sex difference in cardiac disease progression. Like their human counterparts, male mice expressing the R403Q mutation in the heart develop HCM ..
  43. Click chemistry for novel antimicrobials against periodontal pathogens
    Valery V Fokin; Fiscal Year: 2010
    ..bacteria, the diseases disappear, although some of the sequelae such as bone loss become irreversible with disease progression. Accordingly, treatment of periodontitis is focused primarily on removal and elimination of the subgingival ..
  44. Mediators of Atherosclerosis in South Asians Living in America
    Alka M Kanaya; Fiscal Year: 2013
    ..cohort study of 900 South Asian individuals to determine other risk factors linked to atherosclerosis and disease progression. We will conduct a two-center prospective cohort study of 900 South Asian adults between the ages of 40 and ..
  45. Contribution of Gstm1 to the severity of hypertension and chronic kidney disease
    Thu H Le; Fiscal Year: 2013
    ..variant of the GSTM1 gene, a member of the Nrf2 antioxidant pathway, as a modifier of hypertensive kidney disease progression. The gene product of GSTM1 is glutathione S-transferase m-1, or GSTM1 enzyme, that belongs to a superfamily ..
  46. Periostin Regulation of Lung Fibrosis
    Bethany B Moore; Fiscal Year: 2013
    ..periostin levels over time in IPF patients and determine the correlations this biomarker may have on disease progression. We hypothesize that the matricellular protein, periostin, promotes the development and progression of ..
  47. Fatty Acid Defects &Oxidative Stress Modulate Islet Function in Cystic Fibrosis
    Aliye Uc; Fiscal Year: 2013
    ..rapidly in CF ferrets after birth and they develop progressive hyperglycemia, whereas the pancreatic disease progression is slower in CF pigs and they do not develop hyperglycemia as adults...
  48. Combination Clostridium Difficile Toxin and Adhesin Vaccine
    Ciaran P Kelly; Fiscal Year: 2013
    ..of flagellar proteins and toxins in a vaccine could provide protection against colonization as well as disease progression. Key milestones will be to address whether the combination vaccine using toxins and flagellar proteins can ..
  49. Amoeboid Membrane Dynamics in Prostate Cancer
    Michael R Freeman; Fiscal Year: 2013
    ..DRF3 protein expression also declines with disease progression. The mesenchymal-amoeboid transition (MAT) has recently been identified as a dynamic phenotypic transition ..
  50. Gene-Engineered and Targeted Stem Cell Therapy for Myeloma
    Selvarangan Ponnazhagan; Fiscal Year: 2013
    ..at improving myeloma-related bone disease and test treatment efficacy in preventing myeloma relapses and disease progression in human patients...
  51. Cyclic AMP Signaling in Pseudomonas aeruginosa Virulence
    Matthew C Wolfgang; Fiscal Year: 2011
    ..cAMP fluctuations occur during cell culture infection and whether cAMP levels change with time and disease progression in a mouse model of acute pneumonia...
  52. Right Heart-Pulmonary Vascular Interactions in Bronchopulmonary Dysplasia
    Marlowe Eldridge; Fiscal Year: 2013
    ..We have a unique and important opportunity to investigate the consequences of BPD on lung and right heart function in this population, which will inform treatment strategies and predictions of disease progression in the future.
  53. Multi-Organ Autonomic Electrophysiology in Parkinson Disease
    Samay Jain; Fiscal Year: 2013
    ..This challenges current approaches of PD which rely solely on motor impairment as a measure of disease progression. We apply a novel protocol translating techniques from psychophysiology to non-invasively measure autonomic ..
  54. TRANSCRIPTIONAL REPRESSION BY POLYCOMB GROUP PRODUCTS
    Jeffrey A Simon; Fiscal Year: 2012
    ..Overabundance of PcG proteins is also implicated in disease progression in cancers of the breast, prostate, and other tissues...
  55. Epigenetic mechanisms of TDP43-mediated neurodegeneration
    Amit Berson; Fiscal Year: 2013
    ..human patient tissue to define the mechanisms by which this histone methylation mark affects FTD and ALS disease progression. First, rigorous controls in Drosophila will be performed, and the effects of histone methylation on ..
  56. NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment
    Kenneth Cusi; Fiscal Year: 2013
    ..The clinical, metabolic and molecular (liver biopsy) evaluations will identify variables associated with disease progression and help understand how pioglitazone works...
  57. CTRIP: Molecular phenotypes of rapidly progressive idiopathic pulmonary fibrosis
    Galen B Toews; Fiscal Year: 2010
    ..The practical implication of this variability in disease progression is highlighted by the discordant results of two recently reported pirfenidone trials...
  58. microRNAs as novel biomarkers for management of breast cancer
    LORENZO SEMPERE; Fiscal Year: 2012
    ..were designed by NCI Co-operative Breast Cancer Tissue Resources (CBCTR) to find marker associations with disease progression and disease outcome;ii) To validate identified miRNA signatures in an independent cohort of patients from ..
  59. Cx43 phosphorylation modulates Kras mediated pancreas cancer progression
    Paul D Lampe; Fiscal Year: 2012
    ..However, like in humans with pancreas cancer, disease progression, symptom presentation and speed of progression varies even in these syngeneic models...
  60. Role of the Renin-Angiotensin System in the Regulation of Biliary Proliferation
    SHANNON STROUD GLASER; Fiscal Year: 2010
    ..completion of the studies can ultimately be expected to provide a greater understanding of cholestatic liver disease progression and increase opportunities for the development of novel treatment paradigms for chronic liver diseases.
  61. Humanized Transgenic Mice Reproduce the Disease Evolution in Severe RA
    Grete Sonderstrup; Fiscal Year: 2010
    ..similar joint distribution as RA in humans, none of these models accurately replicates the slow, chronic disease progression with extra-articular symptoms seen in humans...
  62. Astrocytes Play a Critical Role in the Pathology of EAE
    JOHN ROLAND BETHEA; Fiscal Year: 2013
    ..Chronic neuroinflammation and demyelination may also contribute to disease progression and chronic neurological deficits...
  63. Polarization and directed cell movements in engineered cellular environments
    Deborah E Leckband; Fiscal Year: 2010
    ..It also drives disease progression in cancer, mental retardation, atherosclerosis, and arthritis...
  64. HOST GENETIC DETERMINANTS OF HIV PATHOGENESIS
    Sunil Ahuja; Fiscal Year: 1999
    ..of CCR5, the coding regions of CCR2B, and the chemokine SDF are associated with altered rates of HIV-1 disease progression (Nature Medicine, 1998)...
  65. A New Insight into HIV-1 Latency Through a Novel in Vitro System
    Fabio Romerio; Fiscal Year: 2010
    ..Viral latency may also affect the natural history of HIV-1 infection and disease progression by playing a role in virus transmission and coreceptor switch...
  66. Longitudinal Studies of Primary Biliary Cirrhosis
    MARLYN MAYO; Fiscal Year: 2006
    ..and DNA for the study of PBC; and 2) to utilize this repository to identify the best surrogate marker of disease progression. PBC is a chronic progressive cholestatic liver disease in which the bile ducts are the target of ..
  67. DEVELOPMENT OF NOVEL BIOMARKERS FOR ALZHEIMER'S DISEASE
    James Moe; Fiscal Year: 2009
    ..novel biomarkers for differential diagnosis of Alzheimer's disease (AD) at early onset and to stage disease progression. Presently, definitive diagnosis of AD requires tissue biopsy or autopsy of the brain, which can occur only ..
  68. Matrix Metalloproteinases and PPAR Gamma in Sarcoidosis
    Daniel Culver; Fiscal Year: 2009
    ..Matrix metalloproteinases (MMPs) are attractive candidate mediators of disease progression in sarcoidosis, since they are capable of facilitating extracellular matrix remodeling, activating ..
  69. Impact of HIV-1 Fitness on Disease Progression
    Eric Arts; Fiscal Year: 2001
    ..infected with clade B and non-clade B HIV-1 and then compare this fitness to various predictors of disease progression. A pilot study revealed a strong correlation between ex vivo HIV-1 fitness and viral load...
  70. Measurement of CCR5 and CCL3L1 on Single Cell by Fluorescent Metal Nanoparticle
    Richard Yuqi Zhao; Fiscal Year: 2010
    ..In addition, it may also provide a prognostic tool to predict disease progression of HIV-infected patients and a possible surrogate marker for testing efficacy of future CCR5-based anti-HIV ..
  71. HIV-related oral diseases among women in Harare
    John Greenspan; Fiscal Year: 2004
    ..Because biologic assays to measure HIV disease progression are rarely accessible in sub-Saharan African countries due to prohibitive cost, other less expensive means ..
  72. Dynamics of SHIV clade C and S mansoni coinfection
    Ruth Ruprecht; Fiscal Year: 2005
    ..While it remains controversial whether HIV transmission and/or disease progression in sub-Saharan Africa differ from those seen in industrialized countries, the high prevalence of parasitic ..